Compare Infosys Limited (INFY) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Infosys Limited vs Recursion Pharmaceuticals Inc — how do they compare? Infosys Limited trades at $11.28 (market cap $46.65B), while Recursion Pharmaceuticals Inc trades at $2.93 (market cap $1.53B). The key difference: Infosys Limited is far larger — about 30.5× Recursion Pharmaceuticals Inc's market cap, and Infosys Limited pays a 4.63% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INFY | RXRX | |
|---|---|---|
Market Cap | $46.65B | $1.53B |
Sector | Technology | Health |
52-Week High | $20.22 | $6.79 |
52-Week Low | $10.49 | $2.84 |
Enterprise Value | $43.87B | $946.50M |
Dividend Yield | 4.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INFY trades at $11.31, down 1.57% on the day, with a bullish technical signal despite bearish moving averages. The stock shows strong profitability with a 16.44% net income margin and 31.57% ROE, supported by recent earnings beats. Recent news highlights AI collaborations with firms like Sentara and GlobalFoundries, positioning the company for growth in enterprise AI services.
The outlook is cautiously optimistic with a consensus price target of $12.28, implying 8.6% upside. Risks include competitive pressures in IT services and potential volatility from sector-wide demand concerns, as seen with Accenture's recent outlook. Analyst sentiment is mixed, with 37.5% buy ratings but a majority hold stance, reflecting balanced near-term expectations.
RXRX trades at $2.89, down 1.87% on the day, reflecting a challenging fundamental backdrop with a net income margin of -851.51% and negative cash flow from operations. The technical picture is bearish, though the stock has beaten earnings estimates for the last three quarters. Recent news highlights its AI-driven drug discovery platform and significant institutional interest, including purchases by Cathie Wood's Ark Invest.
The outlook remains speculative; the high analyst price target of $7.83 suggests significant upside potential, but this is contingent on the company successfully commercializing its pipeline. Key risks include persistent cash burn, intense competition, and the inherent uncertainty of clinical-stage biotech development.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Infosys Limited
Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
